Show simple item record

dc.contributor.authorSpurdle, Amanda Ben
dc.contributor.authorAntoniou, Antonisen
dc.contributor.authorDuffy, David Len
dc.contributor.authorPandeya, Nirmalaen
dc.contributor.authorKelemen, Liviaen
dc.contributor.authorChen, Xiaoqingen
dc.contributor.authorPeock, Susanen
dc.contributor.authorCook, Margareten
dc.contributor.authorSmith, Paulaen
dc.contributor.authorPurdie, David Men
dc.contributor.authorNewman, Bethen
dc.contributor.authorDite, Gillian Sen
dc.contributor.authorApicella, Carmelen
dc.contributor.authorSouthey, Melissa Cen
dc.contributor.authorGiles, Graham Gen
dc.contributor.authorHopper, John Len
dc.contributor.authorChenevix-Trench, Georgiaen
dc.contributor.authorEaston, Douglasen
dc.date.accessioned2011-06-17T14:32:54Z
dc.date.available2011-06-17T14:32:54Z
dc.date.issued2004-12-16en
dc.identifier.issn1465-5411
dc.identifier.urihttp://www.dspace.cam.ac.uk/handle/1810/238259
dc.description.abstractAbstract Introduction The androgen receptor (AR) gene exon 1 CAG repeat polymorphism encodes a string of 9–32 glutamines. Women with germline BRCA1 mutations who carry at least one AR allele with 28 or more repeats have been reported to have an earlier age at onset of breast cancer. Methods A total of 604 living female Australian and British BRCA1 and/or BRCA2 mutation carriers from 376 families were genotyped for the AR CAG repeat polymorphism. The association between AR genotype and disease risk was assessed using Cox regression. AR genotype was analyzed as a dichotomous covariate using cut-points previously reported to be associated with increased risk among BRCA1 mutation carriers, and as a continuous variable considering smaller allele, larger allele and average allele size. Results There was no evidence that the AR CAG repeat polymorphism modified disease risk in the 376 BRCA1 or 219 BRCA2 mutation carriers screened successfully. The rate ratio associated with possession of at least one allele with 28 or more CAG repeats was 0.74 (95% confidence interval 0.42–1.29; P = 0.3) for BRCA1 carriers, and 1.12 (95% confidence interval 0.55–2.25; P = 0.8) for BRCA2 carriers. Conclusion The AR exon 1 CAG repeat polymorphism does not appear to have an effect on breast cancer risk in BRCA1 or BRCA2 mutation carriers.
dc.languageEnglishen
dc.language.isoen
dc.titleThe androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1and BRCA2mutation carriersen
dc.typeArticle
dc.date.updated2011-06-17T14:32:54Z
dc.rights.holderSpurdle et al.; licensee BioMed Central Ltd.
prism.publicationDate2004en
dcterms.dateAccepted2004-11-11en
rioxxterms.versionofrecord10.1186/bcr971en
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2004-12-16en
dc.contributor.orcidAntoniou, Antonis [0000-0001-9223-3116]
dc.contributor.orcidEaston, Douglas [0000-0003-2444-3247]
dc.identifier.eissn1465-542X
rioxxterms.typeJournal Article/Reviewen


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record